Difference between revisions of "Foregut primary carcinomas"
Jump to navigation
Jump to search
(→Foregut: +IHC) |
|||
| Line 12: | Line 12: | ||
*[[Pancreas]].<ref name=pmid23630303>{{cite journal |authors=Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, Blaylock J, Piper Hanley K, Hanley NA |title=Development of the human pancreas from foregut to endocrine commitment |journal=Diabetes |volume=62 |issue=10 |pages=3514–22 |date=October 2013 |pmid=23630303 |pmc=3781486 |doi=10.2337/db12-1479 |url=}}</ref> | *[[Pancreas]].<ref name=pmid23630303>{{cite journal |authors=Jennings RE, Berry AA, Kirkwood-Wilson R, Roberts NA, Hearn T, Salisbury RJ, Blaylock J, Piper Hanley K, Hanley NA |title=Development of the human pancreas from foregut to endocrine commitment |journal=Diabetes |volume=62 |issue=10 |pages=3514–22 |date=October 2013 |pmid=23630303 |pmc=3781486 |doi=10.2337/db12-1479 |url=}}</ref> | ||
*Lower respiratory tract. | *Lower respiratory tract. | ||
==IHC== | |||
Foregut carcinomas are typically: | |||
*CK7 +ve. | |||
*CK20 -ve. | |||
*CDX2 -ve. | |||
A foregut primary panel for liver lesions: | |||
*AE1/AE3, CK7, CK20, CK19, CDX2, CA-125, HepPar-1, GATA3, TTF-1. | |||
==See also== | ==See also== | ||